Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors.

[1]  N. Kaminski,et al.  Suppression of the humoral immune response by cannabinoids is partially mediated through inhibition of adenylate cyclase by a pertussis toxin-sensitive G-protein coupled mechanism. , 1994, Biochemical pharmacology.

[2]  R. Mechoulam,et al.  Search for endogenous ligands of the cannabinoid receptor. , 1994, Biochemical pharmacology.

[3]  R. Mechoulam,et al.  Effects of two endogenous fatty acid ethanolamides on mouse vasa deferentia. , 1994, European journal of pharmacology.

[4]  P. Smith,et al.  The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. , 1994, The Journal of pharmacology and experimental therapeutics.

[5]  M. Herkenham,et al.  Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. , 1994, The Journal of pharmacology and experimental therapeutics.

[6]  S. Childers,et al.  Effects of anandamide on cannabinoid receptors in rat brain membranes. , 1994, Biochemical pharmacology.

[7]  R. Mechoulam,et al.  Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat. , 1994, Neuroendocrinology.

[8]  R. Pertwee,et al.  Cross‐tolerance between delta‐9‐tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212‐2 and anandamide , 1993, British journal of pharmacology.

[9]  S. Almog,et al.  Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. , 1993, Journal of medicinal chemistry.

[10]  S. Munro,et al.  Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.

[11]  D. Deutsch,et al.  Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. , 1993, Biochemical pharmacology.

[12]  K. Mackie,et al.  Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[13]  R. Mechoulam,et al.  Anandamide, a Brain Endogenous Compound, Interacts Specifically with Cannabinoid Receptors and Inhibits Adenylate Cyclase , 1993, Journal of neurochemistry.

[14]  R. Pertwee,et al.  The evidence for the existence of cannabinoid receptors. , 1993, General pharmacology.

[15]  P. Casellas,et al.  Cannabinoid-receptor expression in human leukocytes. , 1993, European journal of biochemistry.

[16]  K. Rice,et al.  Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. , 1993, The Journal of pharmacology and experimental therapeutics.

[17]  R. Mechoulam,et al.  Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. , 1993, European journal of pharmacology.

[18]  A. Hiltunen,et al.  Discriminative stimulus effects and receptor binding of enantiomeric pairs of cannabinoids in rats and pigeons; a comparison. , 1993, The Journal of pharmacology and experimental therapeutics.

[19]  D. Gibson,et al.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.

[20]  N. Kaminski,et al.  Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. , 1992, Molecular pharmacology.

[21]  N. Kaminski,et al.  Inhibition of adenylate cyclase by delta 9-tetrahydrocannabinol in mouse spleen cells: a potential mechanism for cannabinoid-mediated immunosuppression. , 1992, Life sciences.

[22]  M. Johnson,et al.  Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. , 1992, The Journal of pharmacology and experimental therapeutics.

[23]  G Vassart,et al.  Molecular cloning of a human cannabinoid receptor which is also expressed in testis. , 1991, The Biochemical journal.

[24]  G. Cabral,et al.  Effects of marijuana on macrophage function. , 1991, Advances in experimental medicine and biology.

[25]  R. Mechoulam,et al.  Effect of stereospecific cannabinoids on the immune system. , 1991, Advances in experimental medicine and biology.

[26]  T. Klein,et al.  Drugs of Abuse, Immunity, and Immunodeficiency , 1991, Advances in Experimental Medicine and Biology.

[27]  T. Bonner,et al.  Structure of a cannabinoid receptor and functional expression of the cloned cDNA , 1990, Nature.

[28]  R. Watson.  Drugs of abuse and immune function , 1990 .

[29]  A. Howlett,et al.  Determination and characterization of a cannabinoid receptor in rat brain. , 1988, Molecular pharmacology.

[30]  R. Pertwee.  The central neuropharmacology of psychotropic cannabinoids. , 1988, Pharmacology & therapeutics.

[31]  R. Tallarida,et al.  Graded dose—response , 1987 .

[32]  B. Martin.  Cellular effects of cannabinoids. , 1986, Pharmacological reviews.

[33]  R. Tallarida,et al.  Manual of Pharmacologic Calculations: With Computer Programs , 1984 .

[34]  W. Ollis,et al.  Comprehensive organic chemistry : the synthesis and reactions of organic compounds , 1978 .

[35]  N. Suciu-Foca,et al.  Inhibition of Cellular Mediated Immunity in Marihuana Smokers , 1974, Science.

[36]  P. Bender,et al.  Cannabinoids. Structure-activity studies related to 1,2-dimethylheptyl derivatives. , 1973, Journal of medicinal chemistry.

[37]  R. Pertwee.  The ring test: a quantitative method for assessing the ‘cataleptic’ effect of cannabis in mice , 1972, British journal of pharmacology.

[38]  M. Webber.  International Encyclopedia of Pharmacology and Therapeutics , 1972 .

[39]  R. Mechoulam,et al.  The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. , 1971, Journal of the American Chemical Society.

[40]  L. Harris,et al.  The effect of various neurohumoral modulators on the activity of morphine and the narcotic antagonists in the tail-flick and phenylquinone tests. , 1970, The Journal of pharmacology and experimental therapeutics.